A potential explanation for why patients with TP53mut NSCLC have better clinical outcomes on immunotherapy or chemoimmunotherapy treatment is that the loss of the tumor suppressive function of p53 may lead to higher mutation rates and increased numbers of tumor neo-antigens in patients with TP53mut NSCLC.13 The gene discussed is TP53; the disease is non-small cell lung carcinoma.